Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
Charts & Report
Charts and Graphs
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK
|
BSE: 532296
|
ISIN: INE935A01035
|
Industry: Pharmaceuticals
Legal Settlement
Results
|
Strong Performer, Getting Expensive
2384.9000
33.50
(
1.42
%)
NSE
May 27, 2026
15:31 PM
Near 52W High of ₹2474.00
Volume:
541.8K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Glenmark Pharmaceuticals Ltd.
24 Dec 2024
Legal Settlement
Results
2384.90
1.42%
GLENMARK PHARMACEUTICALS
Accumulate:
Glenmark Pharmaceuticals Ltd.
by
Geojit BNP Paribas
Target: 1720
Target
Geojit BNP Paribas
Glenmark Pharma has gained
22.68%
in the last 6 Months
More from Glenmark Pharmaceuticals Ltd.
Recommended
Market closes flat as gains in metal stocks are offset by weakness in HDFC Bank
Trendlyne Marketwatch |
27 May 2026, 03:56PM
What drove FY26’s biggest estimate beats
The Baseline |
27 May 2026, 01:31PM
Earnings Call Transcript - Q4FY20 for Glenmark Pharmaceuticals
|
29 Jun 2020